Skip to Content

Heart Research

For more information about these heart research studies, call 320-251-2700, ext. 57584 or e-mail Heart Research.

CentraCare Heart & Vascular Center takes an active role in heart research. Our goal is to find better ways to prevent, diagnose and treat heart disease so you can live better and longer. 

Why participate in heart research?

  • Early access to new drugs and treatments
  • Help others who have heart problems, both today and in the future
  • Play a role in the discovery of new drugs, treatments and cures

As one of Minnesota's largest heart hospitals, we are one of the few sites in the state with a department dedicated to heart research.

Current research studies

Prevention Studies

AMG-145 20110118 FOURIER: This study looks at an investigational product called AMG 145. It sees whether treatment of dyslipidemia (abnormal amounts of lipids in the blood) with AMG 145 reduces the risk of recurring or additional cardiovascular events in people who have experienced a prior heart attack or stroke and who are taking a highly effective dose of a statin. 

More information

AMG-145 20120153 GLAGOV: This study looks at the changes in the fatty deposits in the walls of the blood vessels of your heart and blood levels of your “good” and “bad” cholesterol when AMG 145 is taken along with your present medical therapy as directed by your doctor, including a medication for the treatment of abnormal cholesterol blood levels called “statins.” AMG 145 and placebo are given by subcutaneous injection. A subcutaneous injection is an injection given into the tissue just below the skin. In this study, the effects of AMG 145 will be determined by an intravascular ultrasound (IVUS) that measures the amount of fatty deposits in the arteries of your heart.

More information

Camellia: The study looks at the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of major adverse cardiovascular events and conversion to Type 2 diabetes mellitus in overweight subjects with cardiovascular disease or multiple cardiovascular risk factors. 

More information

CIRT: 
The Cardiovascular Inflammation Reduction Trial (CIRT) looks at whether taking low-dose methotrexate reduces heart attacks, strokes or death in people with type 2 diabetes or metabolic syndrome who have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).

More information

Declare: This study will determine whether treatment with dapagliflozin compared with placebo when added to a patient's current therapy for diabetes is effective in reducing cardiovascular events. Dapagliflozin lowers glucose levels in the blood by lowering the effect of sodium-glucose transporters. Dapagliflozin inhibits the sodium-glucose transporters and lowers glucose by allowing glucose removal through the urine.

More information

Exscel: This study compares the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of cardiovascular-related death, nonfatal myocardial infarction (MI), or nonfatal stroke.

More information

GLORIA-AF: This is a registry study for patients recently diagnosed with atrial fibrillation.

More information

Odyssey: This study determines whether a study drug (SAR236553) might prevent future cardiovascular events (such as, heart attacks or strokes) in patients who recently experienced a coronary event.

More information

REDUCE-IT: AMR101 has been investigated as a therapy to lower triglyceride levels. It is thought that AMR101, in combination with a statin drug (such as Lipitor®), will have a greater effect in preventing a cardiovascular event (like a heart attack or stroke) than if you were taking a statin drug alone.

More information

Turbulence: This study evaluates the accuracy of the CADence device in identifying the existence of clinically significant coronary artery disease. Subjects will be evaluated with the device using three sets of data collected from four thorax sites, taking approximately 15 minutes to perform. The patient will then undergo nuclear stress testing followed by either CT or standard coronary angiogram.

More information

Heart Failure Studies

Paragon: This study evaluates the effect of LCZ696 compared to valsartan in the reduction of cardiovascular death and heart failure (HF) hospitalizations in HF patients with preserved ejection fraction.

More information

Device Studies

Micra “Leadless Pacemaker:" This study looks at the safety and efficacy of the Micra Transcatheter Pacing System and assesses its long-term performance. 

More information

INOVATE-HF: The study will demonstrate the long-term safety and efficacy of vagus nerve stimulation with the CardioFit® system for the treatment of people with heart failure.

More information

LSS-4 SITE: Post-approval studies of implanted leads provide an opportunity to observe and assess patient outcomes and technology performance in a real-world setting. The goal of the study is to evaluate, document and report on the appropriate clinical performance, long-term reliability and the functional integrity of the Boston Scientific ENDOTAK RELIANCE® 4-SITE™ Lead and the pulse generator 4-SITE Header.

More information 

Navigate: The NAVIGATE X4 study gathers data to establish the safety, performance and effectiveness of the ACUITY™ X4 quadripolar coronary venous leads and the RELIANCE 4-FRONT™ ventricular defibrillation leads to satisfy FDA requirements for pre-market submission. Additionally, data from this study will be used to support post-market approval requirements for the ACUITY X4 and RELIANCE 4-FRONT leads. 

More information

The CentraCare Heart & Vascular Center Research Department undergoes rigorous review from the St. Cloud Hospital Institutional Review Board (IRB). The purpose of the IRB is to protect the rights and safety of people who volunteer to take part in research studies. To contact the IRB, call 320-255-5785.

Connect With CentraCare